
NovaBridge Biosciences fell 81.9% from $4.54 to $0.82, behind the S&P 500's +10.6%. Its worst day was Mar 30 (−11.8%), and its low came Nov 16 at $0.79.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
NovaBridge Biosciences closed at its highest level of the year, 2.0% above where the year started.
+2.9% · S&P 500 +0.4%
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR
Story events cover the past 12 months · Times ET
−11.2% · S&P 500 +0.6%
NovaBridge Biosciences shares rose 11.1%, while the S&P 500 rose 1.9%.
+11.1% · S&P 500 +1.9%
NovaBridge Biosciences shares rose 17.0%, while the S&P 500 fell 0.6%.
+17.0% · S&P 500 −0.6%
NovaBridge Biosciences shares fell 11.8%, while the S&P 500 fell 0.3%.
−11.8%, the year's worst day · S&P 500 −0.3%
EPS of $-0.21 beat the $-0.22 estimate on $0.00 revenue.
−1.2% · S&P 500 +2.5%
NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the
+20.7%, the year's best day · S&P 500 +1.6%
EPS of $-0.33 missed the $-0.14 estimate on $0.00 revenue.
−3.5% · S&P 500 −0.8%
NovaBridge Biosciences shares fell 11.3%, while the S&P 500 rose 0.7%.
−11.3% · S&P 500 +0.7%
Where it ended: a close of $0.82 on Nov 17, 2026.
Nothing in the past 12 months.
All NBP dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NBP and SPY from Benzinga historical bars. Not investment advice.